Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Med Virol ; 89(12): 2207-2216, 2017 12.
Article in English | MEDLINE | ID: mdl-28853217

ABSTRACT

Undifferentiated nasopharyngeal carcinoma (NPC) is 100% associated with Epstein-Barr virus (EBV). Expression of viral proteins in the tumor cells is highly restricted. EBV reactivation by CytoLytic Virus Activation (CLVA) therapy triggers de novo expression of early viral kinases (PK and TK) and uses antiviral treatment to kill activated cells. The mechanism of tumor elimination by CLVA was analyzed in NPC mouse model using C666.1 cells. Valproic acid (VPA) was combined with gemcitabine (GCb) to stimulate EBV reactivation, followed by antiviral treatment with ganciclovir (GCV). A single cycle of CLVA treatment resulted in specific tumor cell killing as indicated by reduced tumor volume, loss of EBV-positive cells in situ, and paralleled by decreased EBV DNA levels in circulation, which was more pronounced than treatment with GCb alone. In vivo reactivation was confirmed by presence of lytic gene transcripts and proteins in tumors 6 days after GCb/VPA treatment. Virus reactivation was visualized by [124 I]-FIAU accumulation in tumors using PET-scan. This studied showed that CLVA therapy is a potent EBV-specific targeting approach for killing tumor cells. The [124 I]-FIAU appears valuable as PET tracer for studies on CLVA drug dosage and kinetics in vivo, and may find clinical application in treatment monitoring.


Subject(s)
Antiviral Agents/therapeutic use , Carcinoma/virology , Epstein-Barr Virus Infections/drug therapy , Herpesvirus 4, Human/drug effects , Nasopharyngeal Neoplasms/virology , Virus Activation , Animals , Antiviral Agents/blood , Antiviral Agents/pharmacology , Carcinoma/drug therapy , DNA, Viral/genetics , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacology , Disease Models, Animal , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/virology , Ganciclovir/administration & dosage , Ganciclovir/blood , Ganciclovir/therapeutic use , Herpesvirus 4, Human/physiology , Humans , Mice , Mice, Nude , Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms/drug therapy , Treatment Outcome , Tumor Cells, Cultured , Valproic Acid/pharmacology , Valproic Acid/therapeutic use , Viral Load/methods , Gemcitabine
2.
Eur Arch Otorhinolaryngol ; 273(6): 1557-67, 2016 Jun.
Article in English | MEDLINE | ID: mdl-25929413

ABSTRACT

This study estimated the value of quantitative measurements of EBV markers in the clinical management of nasopharyngeal carcinoma in a non-endemic area. The aim was to predict prognosis and detect recurrent and residual disease. In 72 patients, EBV DNA load in blood and nasopharyngeal brushes, and IgA VCA-p18 and EBNA1 in plasma were measured at different time points. At diagnosis and post-treatment, a cut-off value was used for detecting disease [positive (PPV) and negative (NPV) predictive value]. The markers were correlated as a continuous variable with tumor stage, disease-free survival (DFS) and overall survival (OS). The Cox hazard ratio model assessed hazard ratios. At diagnosis, the markers were above the COV in 45, 92, 85 and 83 % of the patients, respectively. Post-treatment, DNA load test in blood and brush had the best discriminating power (blood DNA load test: PPV 39 % and NPV 97 %, brush for local disease: PPV 75 % and NPV 99 %). Post-treatment, DNA load in blood was the best predictor for OS and DFS [hazard ratio 3.2 (95 % CI 1.51-3.5) and 2.3 (95 % CI 1.72-5.8)]. Assessing the EBV DNA load in blood has significant prognostic value, although the clinical value is for discussion. The EBV DNA load in the brush might improve early detection of local failures post-treatment.


Subject(s)
DNA, Viral/isolation & purification , Herpesvirus 4, Human/genetics , Nasopharyngeal Neoplasms/virology , Neoplasm Recurrence, Local/virology , Adult , Aged , DNA, Viral/blood , Disease-Free Survival , Early Diagnosis , Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Nuclear Antigens/blood , Female , Herpesvirus 4, Human/isolation & purification , Humans , Male , Middle Aged , Nasopharyngeal Neoplasms/diagnosis , Nasopharyngeal Neoplasms/mortality , Neoplasm Recurrence, Local/mortality , Neoplasm, Residual , Netherlands , Prognosis , Prospective Studies , Viral Load
3.
J Cancer Res Clin Oncol ; 141(10): 1845-57, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25920375

ABSTRACT

PURPOSE: Despite successful primary treatment of nasopharyngeal carcinoma (NPC), the incidence of distant metastasis remains 25-34 %. Treatment options are limited, and survival is poor. Intratumoural Epstein-Barr virus (EBV) was used as treatment target. In NPC, EBV is present in a latent state, expressing only few non-immunogenic viral products. Gemcitabine and valproic acid can trigger EBV to the lytic state, wherein viral kinases are expressed, making EBV-positive tumour cells susceptible for antiviral therapy with, i.e. valganciclovir, and inducing an EBV-specific immune response. METHODS: This drug combination was applied in eight patients with EBV-positive NPC, refractory to conventional treatment. The primary endpoints were safety, tolerability and clinical response. Secondary endpoint was to get proof of concept based on biomarkers, i.e. pharmacokinetics, EBV-DNA load in whole blood and nasopharyngeal brushes, EBV-RNA profiling for proof of lytic induction, EBV-IgG and EBV-IgA levels and diversity and EBV-specific T cell response. RESULTS: The best observed clinical response was partial in two patients (25 %) and stable disease in three patients (37.5 %). The median survival was 9 months (95 % confidence interval 7-17 months). Effective dose levels were reached. Peaking of EBV-DNA loads in blood and brush proved the biological effect on EBV during most treatment cycles. In one patient, RNA profiling confirmed lytic EBV induction. EBV-IgG and EBV-IgA antibody levels were already high before treatment and did not change during treatment. No changes in EBV-specific T cell response were detected. CONCLUSION: The treatment was safe with manageable side effects, clinical response was observed, and viral activation corroborated.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Herpesvirus 4, Human/drug effects , Nasopharyngeal Neoplasms/drug therapy , Adult , Antibodies, Viral/immunology , Carcinoma , DNA, Viral/blood , DNA, Viral/immunology , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Female , Herpesvirus 4, Human/immunology , Humans , Immunoglobulin A/immunology , Immunoglobulin G/immunology , Male , Middle Aged , Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms/blood , Nasopharyngeal Neoplasms/immunology , Nasopharyngeal Neoplasms/virology , T-Lymphocytes/drug effects , Valproic Acid/administration & dosage , Virus Latency/drug effects , Virus Latency/immunology , Gemcitabine
4.
Clin Cancer Res ; 18(18): 5061-70, 2012 Sep 15.
Article in English | MEDLINE | ID: mdl-22761471

ABSTRACT

PURPOSE: Nasopharyngeal carcinoma (NPC) is causally linked to Epstein-Barr virus (EBV) infection. Because all tumor cells carry EBV, the virus itself is a potential target for therapy. In these tumor cells, EBV hides in a latent state and expresses only a few non-immunogenic proteins for EBV maintenance and contributes to tumor growth. We developed a cytolytic virus activation (CLVA) therapy for NPC treatment, reactivating latent EBV, triggering immune recognition, and inducing susceptibility to antiviral therapy. EXPERIMENTAL DESIGN: CLVA therapy combines gemcitabine (GCb) and valproic acid (VPA) for virus activation and tumor clearance with (val)ganciclovir (GCV) as the antiviral drug to block virus replication and kill proliferating virus-infected cells. CLVA treatment was optimized and validated in NPC cell lines and subsequently tested in 3 Dutch patients with NPC that was refractory to conventional treatment. RESULTS: In NPC cell lines, both GCb and VPA can induce the lytic cycle of EBV. Their combination resulted in a strong synergistic effect. The addition of GCV resulted in higher cytotoxicity compared with chemotherapy alone, which was not observed in EBV-negative cells. CLVA therapy was analyzed in 3 patients with end-stage NPC. Patients developed increased levels of viral DNA in the circulation originating from apoptotic tumor cells, had disease stabilization, and experienced improved quality of life. CONCLUSIONS: Our results in the initial CLVA-treated patients indicate that the therapy had a biological effect and was well tolerated with only moderate transient toxicity. This new virus-specific therapy could open a generic approach for treatment of multiple EBV-associated malignancies.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Herpesvirus 4, Human/drug effects , Nasopharyngeal Neoplasms/drug therapy , Virus Activation/drug effects , Antibodies, Viral/blood , Antibodies, Viral/immunology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Carcinoma , Cell Line, Tumor , DNA, Viral/genetics , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Dose-Response Relationship, Drug , Female , Herpesvirus 4, Human/immunology , Herpesvirus 4, Human/pathogenicity , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Male , Middle Aged , Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms/pathology , Nasopharyngeal Neoplasms/virology , Neoplasm Staging , Treatment Outcome , Valproic Acid/administration & dosage , Viral Load , Gemcitabine
5.
J Am Soc Nephrol ; 23(5): 842-53, 2012 May.
Article in English | MEDLINE | ID: mdl-22343118

ABSTRACT

Inhibition of the mammalian target of rapamycin (mTOR) shows beneficial effects in animal models of polycystic kidney disease (PKD); however, two clinical trials in patients with autosomal dominant PKD failed to demonstrate a short-term benefit in either the early or progressive stages of disease. The stage of disease during treatment and the dose of mTOR inhibitors may account for these differing results. Here, we studied the effects of a conventional low dose and a higher dose of sirolimus (blood levels of 3 ng/ml and 30-60 ng/ml, respectively) on mTOR activity and renal cystic disease in two Pkd1-mutant mouse models at different stages of the disease. When initiated at early but not late stages of disease, high-dose treatment strongly reduced mTOR signaling in renal tissues, inhibited cystogenesis, accelerated cyst regression, and abrogated fibrosis and the infiltration of immune cells. In contrast, low-dose treatment did not significantly reduce renal cystic disease. Levels of p-S6Rp(Ser240/244), which marks mTOR activity, varied between kidneys; severity of the renal cystic phenotype correlated with the level of mTOR activity. Taken together, these data suggest that long-term treatment with conventional doses of sirolimus is insufficient to inhibit mTOR activity in renal cystic tissue. Mechanisms to increase bioavailability or to target mTOR inhibitors more specifically to kidneys, alone or in combination with other compounds, may improve the potential for these therapies in PKD.


Subject(s)
Immunosuppressive Agents/pharmacology , Polycystic Kidney Diseases/drug therapy , Signal Transduction/drug effects , Sirolimus/pharmacology , TOR Serine-Threonine Kinases/antagonists & inhibitors , Animals , Dose-Response Relationship, Drug , Female , Male , Mice , Mice, Inbred C57BL , Polycystic Kidney Diseases/pathology , TOR Serine-Threonine Kinases/physiology
6.
Am J Physiol Renal Physiol ; 300(5): F1193-202, 2011 May.
Article in English | MEDLINE | ID: mdl-21345977

ABSTRACT

Autosomal dominant polycystic kidney disease (ADPKD) caused by mutations in either the PKD1 or PKD2 gene is a major cause of end-stage renal failure. A number of compounds targeting specific signaling pathways were able to inhibit cystogenesis in rodent models and are currently being tested in clinical trials. However, given the complex signaling in ADPKD, an ideal therapy would likely have to comprise several pathways at once. Therefore, multitarget compounds may provide promising therapeutic interventions for the treatment of ADPKD. To test this hypothesis, we treated Pkd1-deletion mice with diferuloylmethane (curcumin), a compound without appreciable side effects and known to modulate several pathways that are also altered in ADPKD, e.g., mammalian target of rapamycin (mTOR) and Wnt signaling. After conditional inactivation of Pkd1, mTOR signaling was indeed elevated in cystic kidneys. Interestingly, also activation of signal transducers and activator of transcription 3 (STAT3) strongly correlated with cyst progression. Both pathways were effectively inhibited in vitro by curcumin. Importantly, Pkd1-deletion mice that were treated with curcumin and killed at an early stage of PKD displayed improved renal histology and reduced STAT3 activation, proliferation index, cystic index, and kidney weight/body weight ratios. In addition, renal failure was significantly postponed in mice with severe PKD. These data suggest that multitarget compounds hold promising potential for safe and effective treatment of ADPKD.


Subject(s)
Curcumin/pharmacology , Kidney/drug effects , Polycystic Kidney, Autosomal Dominant/prevention & control , Renal Insufficiency/prevention & control , Signal Transduction/drug effects , TRPP Cation Channels/deficiency , Animals , Cell Proliferation/drug effects , Cells, Cultured , Cytoprotection , Disease Models, Animal , Dose-Response Relationship, Drug , Kidney/enzymology , Kidney/pathology , Mice , Mice, Knockout , Organ Size/drug effects , Phosphorylation , Polycystic Kidney, Autosomal Dominant/enzymology , Polycystic Kidney, Autosomal Dominant/genetics , Polycystic Kidney, Autosomal Dominant/pathology , Renal Insufficiency/enzymology , Renal Insufficiency/genetics , Renal Insufficiency/pathology , Ribosomal Protein S6/metabolism , STAT3 Transcription Factor/metabolism , TOR Serine-Threonine Kinases/metabolism , TRPP Cation Channels/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...